Soleno Therapeutics (NASDAQ:SLNO) Announces Quarterly Earnings Results

Soleno Therapeutics (NASDAQ:SLNO) released its quarterly earnings results on Wednesday. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16, FiscalAI reports. The company had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million.

Here are the key takeaways from Soleno Therapeutics’ conference call:

• Strong financial launch: Q4 net revenue was $91.7M (FY2025 net revenue $190.4M on <9 months of sales), Soleno reached profitability (FY net income $20.9M), generated $48.7M cash from operations in Q4, and finished the year with ~$506M in cash and marketable securities, providing runway for commercialization and expansion.
• Commercial traction: Since launch there were 1,250 patient start forms (~12.5% of the U.S. addressable market), 859 active patients, 630 unique prescribers, and coverage for >180M lives, with the company targeting ~1,000 additional start forms over the next 9–12 months.
• Safety and retention: Real-world safety so far mirrors clinical expectations; launch-to-date discontinuation related to adverse events is ~12% (total discontinuation ~15%), and management expects a long-term discontinuation rate of 15–20%.
• EU regulatory progress: The MAA for DCCR (VYKAT XR) was validated, Day‑120 questions were answered, Day‑180 questions are expected imminently and a mid‑2026 EMA decision is anticipated; the company is preparing commercialization options for a meaningful EU market.
• Pipeline expansion plans: Soleno plans to file an IND for Glycogen Storage Disease Type I in H1 2026 and initiate a clinical program in late 2026, has orphan designations in US/EU, and is evaluating other rare-disease indications leveraging the same mechanism.

Soleno Therapeutics Trading Up 4.7%

NASDAQ:SLNO opened at $41.01 on Thursday. The company has a market cap of $2.20 billion, a PE ratio of -22.29 and a beta of -3.16. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. The company has a 50 day simple moving average of $43.01 and a two-hundred day simple moving average of $53.97. Soleno Therapeutics has a 12 month low of $36.67 and a 12 month high of $90.32.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on SLNO shares. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a research note on Monday, January 12th. HC Wainwright reiterated a “buy” rating and set a $120.00 price target (up from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. Finally, Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.62.

Hedge Funds Weigh In On Soleno Therapeutics

Institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new position in shares of Soleno Therapeutics in the second quarter worth approximately $25,000. Danske Bank A S bought a new stake in shares of Soleno Therapeutics during the 3rd quarter valued at $27,000. Global Retirement Partners LLC increased its stake in shares of Soleno Therapeutics by 519.0% in the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after purchasing an additional 519 shares in the last quarter. Quarry LP purchased a new stake in shares of Soleno Therapeutics in the 3rd quarter worth $47,000. Finally, Osaic Holdings Inc. raised its holdings in Soleno Therapeutics by 97.7% in the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock worth $72,000 after purchasing an additional 423 shares during the period. Institutional investors own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.